We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
-7.78%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$1.62B
AUM Growth
-$116M
(-6.7%)
Cap. Flow
+$444M
Cap. Flow
% of AUM
27.45%
Top 10 Holdings %
Top 10 Hldgs %
37.93%
Holding
108
New
37
Increased
28
Reduced
11
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Burlington
BURL
|
+$54.3M |
| 2 |
Energizer
ENR
|
+$39.6M |
| 3 |
Amazon
AMZN
|
+$36.8M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$35.3M |
| 5 |
Avalo Therapeutics
AVTX
|
+$27.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Williams-Sonoma
WSM
|
+$32.8M |
| 2 |
AutoZone
AZO
|
+$29.4M |
| 3 |
Envista
NVST
|
+$25.1M |
| 4 |
Biogen
BIIB
|
+$21.2M |
| 5 |
Estee Lauder
EL
|
+$20.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.87% |
| 2 | Consumer Staples | 13.75% |
| 3 | Consumer Discretionary | 13.46% |
| 4 | Technology | 4.19% |
| 5 | Industrials | 2.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MNK
51
CALL
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $10.3M | 0.64% |
52,000
+12,000
| +30% | +$45.5K |
|
52
Ross Stores
ROST
$80.7B
| $10.2M | 0.63% |
+117,714
| New | +$12.6M |
|
53
CRISPR Therapeutics
CRSP
$5.1B
| $10M | 0.62% |
236,000
+88,000
| +59% | +$4.54M |
|
54
Kiora Pharmaceuticals
KPRX
$11.3M
| $9.44M | 0.58% |
5,043
+64
| +1% | +$138K |
|
55
Lowe's Companies
LOW
$123B
| $9.4M | 0.58% |
+109,239
| New | +$11.9M |
|
|
AIMT
56
DELISTED
Aimmune Therapeutics
AIMT
| $8.65M | 0.54% |
+600,000
| New | +$15.3M |
|
|
ATVI
57
DELISTED
Activision Blizzard
ATVI
| $8.09M | 0.5% |
+136,000
| New | +$8.07M |
|
58
Thermo Fisher Scientific
TMO
$214B
| $7.94M | 0.49% |
+28,000
| New | +$8.83M |
|
|
ADMS
59
DELISTED
Adamas Pharmaceuticals
ADMS
| $7.92M | 0.49% |
2,742,000
+546,000
| +25% | +$2.45M |
|
60
Domino's
DPZ
$11.7B
| $7.89M | 0.49% |
+24,342
| New | +$7.51M |
|
61
Uber
UBER
$147B
| $7.59M | 0.47% |
+272,000
| New | +$8.95M |
|
62
TG Therapeutics
TGTX
$7.63B
| $7.56M | 0.47% |
768,000
-32,000
| -4% | -$404K |
|
63
BWX Technologies
BWXT
$15.5B
| $4.87M | 0.3% |
+100,000
| New | +$5.94M |
|
|
SMAR
64
DELISTED
Smartsheet Inc.
SMAR
| $4.48M | 0.28% |
+108,000
| New | +$4.9M |
|
|
ZEN
65
DELISTED
ZENDESK INC
ZEN
| $3.71M | 0.23% |
+58,000
| New | +$4.53M |
|
66
Korn Ferry
KFY
$4.23B
| $3.65M | 0.23% |
+150,000
| New | +$5.53M |
|
67
Addus HomeCare
ADUS
$2.21B
| $3.52M | 0.22% |
+52,000
| New | +$4.5M |
|
68
Bath & Body Works
BBWI
$4.04B
| $3.03M | 0.19% |
+324,235
| New | +$5.15M |
|
|
NTGN
69
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
| $2.77M | 0.17% |
+1,050,000
| New | +$1.72M |
|
|
TTPH
70
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $1.82M | 0.11% |
1,419,507
+1,270,000
| +849% | +$2.59M |
|
71
Minerva Neurosciences
NERV
$202M
| $1.81M | 0.11% |
37,500
-32,500
| -46% | -$1.96M |
|
|
PGNX
72
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $1.33M | 0.08% |
+350,000
| New | +$1.51M |
|
73
NN Inc
NNBR
$289M
| $865K | 0.05% |
500,000
+207,979
| +71% | +$1.49M |
|
74
Outlook Therapeutics
OTLK
$191M
| $849K | 0.05% |
+70,619
| New | +$1.17M |
|
75
Solana Company
HSDT
$98.7M
| $607K | 0.04% |
+1
| New | +$1.08M |
|
Similar funds
CRC
RMDI
F
EW
O
DSC
ACM
PI
Armistice Capital's Q1 2020 Portfolio in Review
As of Q1 2020, Armistice Capital held 108 positions worth $1.62B, down 6.7% from $1.73B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Armistice Capital deployed $444M of net new capital in Q1 2020, opening 37 new positions and adding to 28 existing holdings. Its largest new stake was Burlington: 258,004 shares worth $40.9M.
By sector, the portfolio is most concentrated in Healthcare at 47% of assets, up from 42% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
On the sell side, the largest reduction was Biogen, an estimated $21.2M trimmed.
- Armistice Capital's largest Q1 2020 buy was Burlington: 258,004 shares worth $40.9M.
- Armistice Capital added most to Amazon in Q1 2020, an estimated $36.8M increase.
- Armistice Capital's biggest Q1 2020 reduction was Biogen, cutting an estimated $21.2M.
- Armistice Capital fully exited Williams-Sonoma in Q1 2020, selling an estimated $32.8M.
- Armistice Capital's ten largest holdings make up 38% of its $1.62B portfolio in Q1 2020.
- Armistice Capital opened 37 new positions and closed 29 in Q1 2020.
- Armistice Capital's portfolio value fell 6.7% quarter-over-quarter to $1.62B.
Based on Armistice Capital's 13F filing for Q1 2020, filed 15 May 2020.